**Profound systemic alteration of the immune phenotype and an immunoglobulin switch in Erdheim–Chester disease in a single-center of 78 patients**

Fleur COHEN AUBART1**\***, Lucie POUPEL4**\***, Flora SAINT-CHARLES4, Frédéric CHARLOTTE2, Youssef ARSAFI4, Eric FRISDAL4,Damien ROOS-WEIL2, Jean-François EMILE3, Zahir AMOURA1, Maryse GUERIN4, Philippe LESNIK4, Julien HAROCHE1 and Wilfried LE GOFF4

1- Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Service de Médecine Interne 2, Centre National de Référence Maladies Systémiques Rares et Histiocytoses, Hôpital Pitié-Salpêtrière, 75013-Paris, France.

2- Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Service d'anatomopathologie, Hôpital Pitié-Salpêtrière, 75013-Paris, France.

3- EA4340, Université Versailles-Saint Quentin, Assistance Publique-Hôpitaux de Paris, Hôpital Ambroise Paré, Département de Pathologie, Boulogne-92100, France.

4- Sorbonne Université, Inserm, Institute of Cardiometabolism and Nutrition (ICAN), UMR\_S1166, F-75013 Paris, France.

\*The first two authors contributed equally to this work.

Correspondence:

Julien Haroche, M.D., Ph.D. Wilfried Le Goff, Ph.D.

Service de Médecine Interne 2 INSERM UMR\_S1166

Groupe Hospitalier Pitié-Salpêtrière Faculté de médecine Sorbonne Université

47-83, boulevard de l’Hôpital 91, boulevard de l’Hôpital

75013 Paris 75013 Paris

France France

email: Julien.haroche@psl.aphp.fr email: wilfried.le\_goff@sorbonne-universite.fr

Financial support: INSERM, Sorbonne Université, French National Agency (ANR-10-IAHU-05), and the Erdheim-Chester Disease Global Alliance.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Running title: Alteration of the systemic immune cell phenotype in ECD.

**Abstract**

Erdheim–Chester disease (ECD) is a rare, systemic, non-Langerhans cell histiocytosis neoplasm, which is characterized by the infiltration of CD63+ CD1a- histiocytes in multiple tissues. The *BRAF*V600E mutation is frequently present in individuals with ECD and has been detected in hematopoietic stem cells and immune cells from the myeloid and systemic compartments. Immune cells and pro-inflammatory cytokines are present in lesions, suggesting ECD involves immune cell recruitment. Although a systemic cytokine Th-1-oriented signature has been reported in ECD, the immune cell network orchestrating the immune response in ECD has yet to be described. To address this question, the phenotypes of circulating leukocytes were investigated in a large, single-center cohort of 78 patients with ECD and compared with a group of 21 control individuals. Major perturbations in the abundance of systemic immune cells were detected in patients with ECD, with a decrease in circulating plasmacytoid, myeloid 1, and myeloid 2 dendritic cells, mostly in *BRAF*V600E carriers, in comparison with individuals in the control group. Similarly, a marked decrease in blood conventional T-helper, cytotoxic, and B lymphocyte numbers was observed in patients with ECD, relative to the control group. Measurement of circulating immunoglobulin concentrations revealed an immunoglobulin G switch, from IgG1 to IgG4 subclasses, which are more frequently associated with the *BRAF* mutation. First-line therapies, including pegylated IFNα and vemurafenib, were able to correct most of these alterations. This study reports a profound disturbance in the systemic immune phenotype in patients with ECD, providing important new information and helping to understand the physiopathological mechanisms involved in this rare disease and in the therapeutic management of patients.

**Introduction**

Erdheim–Chester Disease (ECD) is a rare, systemic, non-Langerhans cell histiocytosis neoplasm, frequently caused by mutations in the MEK-extracellular signal-regulated kinase (ERK) signaling pathway; these are mostly *BRAF* mutations 1. ECD is characterized by the infiltration of tissues by foamy histiocytes expressing markers of the monocyte/macrophage lineage, including CD45, CD68, CD163, and CD14, whereas ECD histiocytes are negative for CD1a and CD207 dendritic cell markers. It is proposed that in ECD, histiocytes originate from myeloid CD34+ and CD14+ progenitor cells 2,3. The *BRAF*V600E mutation has been detected in hematopoietic stem cells (HSCs), including common myeloid progenitors (CMPs) and granulocyte-macrophage progenitors (GMPs), in the bone marrow of patients with ECD 2, supporting a model in which *BRAF*-mutated myeloid cells disseminate from bone marrow to the periphery for tissue infiltration. Consistent with this model, the *BRAF*V600E mutation was also found in circulating leucocytes, including classical (CD14+) and nonclassical (CD16+) monocytes and CD1c+ myeloid dendritic cells in individuals with ECD 2.

The accumulation of histiocytes within lesions in cases of ECD is accompanied by the expression of a chemokine and cytokine network favoring immune cell recruitment 4,5. Indeed, pro-inflammatory cytokines are highly expressed in ECD lesions, together with the infiltration of pro-inflammatory T-cell helper 1 (Th-1) lymphocytes. In addition, immunohistological examination of ECD biopsies revealed that infiltrated histiocytes express a large set of chemokines and chemokine receptors 4. Consistent with these observations, patients with ECD exhibited a systemic immune Th1-oriented cytokine profile 6, thereby providing important clues for the therapeutic management of these patients. However, the therapeutic management of patients with ECD remains difficult. First-line therapies are mostly determined by the severity of the disease. Thus, pegylated interferon-α (IFNα) is used to treat mild disease and nonrefractory ECD 7, whereas drugs targeting the mutated BRAF, such as vemurafenib, are used in multisystemic and refractory ECD 8.

The underlying mechanisms that orchestrate the immune response in ECD remain largely unknown, and a comprehensive characterization of systemic immune cells in ECD patients is lacking. Therefore, the goal of our study was to determine whether patients with ECD exhibit abnormalities in their systemic immune phenotype and whether this is affected by the presence of the *BRAF* mutation and therapeutic agents. We demonstrated that patients with ECD exhibited a profound alteration in their systemic immune cell phenotype, characterized by a low abundance of dendritic cell subsets and by specific lymphocyte populations, together with a switch in immunoglobulin (Ig) G subclasses, which may be partially corrected by first-line therapies.

**Patients and Methods.**

**Patients.** Fasting blood samples were obtained from 17 healthy individuals who formed the control group (13 male and 4 female; mean age, 53±25 years, range, 21–90 years) and 78 patients with ECD (60 male and 18 female; mean age, 60±14 years, range, 18–84 years) who were followed at the Pitié-Salpêtrière Hospital, Paris, France, between December 2012 and July 2015 (Supplemental Table 1). For all patients, ECD was diagnosed based on the consensus guidelines for the diagnosis and clinical management of ECD 9. The detection of the *BRAF*V600E mutation was performed using multiplex picodroplet digital PCR (Raindance Technologies), as previously described 10. The prevalence of the *BRAF*V600E mutation was 64% in the ECD group (50/71 patients, indeterminate for 7 patients). The absence of the *BRAF*V600E mutation in ECD patients was referred to as the wild-type (WT) in this study. At the time of the collection, the patients were free of any treatment (n=42) or were receiving treatment, either pegylated IFN-α (n=31), vemurafenib (n=13), or others (n=17). Blood samples were collected from 25 patients at several time points (free of any treatments and upon treatment). This study was approved by the ethics committee Ile de France III (#2011-A00447-34) and was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all patients.

**Analysis of blood immune cells by flow cytometry.** Fresh blood samples were collected in EDTA tubes at the same time of the day for all patients and control individuals; the samples were used immediately for the flow cytometry analysis. Analysis of blood immune cells was carried out simultaneously in both patients and control individuals throughout the study (2013–2015). Similar blood immune cell counts were obtained when flow cytometry analysis was performed for the same control individual at different times of the study. A 100- or 300-μl aliquot was used for immunostaining of monocytes, lymphocytes, or dendritic cells (DCs), respectively. Samples were blocked with 200 μl of 1/400 diluted Fc Blocking reagent (Miltenyi) and then incubated with corresponding antibodies for 30 min at 4°C, protected from exposure to light. If necessary, 50 μl of 1/200 diluted streptavidin PE Texas Red (BD Biosciences) was added and samples were incubated for 15 min at 4°C protected from light exposure (final dilution 1/1400). Then, red blood cells were lysed and leukocytes were fixed with 700 μl (for lymphocytes and monocytes) or 1300 μl (for DCs) of Versafix solution (Beckman Coulter), according to the manufacturer’s instructions. Distinctions among lymphocyte subsets were based on different expression patterns of surface markers, as previously described 11: T helper cells (CD45+, CD3+, CD4+, CD8-,CD25-, CD127+), T regulatory cells (CD25+, CD127-), cytotoxic lymphocytes (CD45+, CD3+, CD4-, CD8+), and B lymphocytes (HLA-DR+, CD19+). Monocyte subsets were distinguished as classical (CD14++/CD16-), intermediary (CD14++/CD16+), and nonclassical (CD14+/CD16++) monocytes. DC subsets were identified according to their plasmacytoid (CD11c-, CD123+, BDCA2+(CD303)), myeloid 1 (CD11c+, BDCA1+(CD1c+), BDCA3-(CD141-)), or myeloid 2 lineages (CD11c+, BDCA1-(CD1c-), BDCA3+(CD141+)). Samples were acquired on LSR II FORTESSA SORP (BD Biosciences) and the results were analyzed using FACSDIVA software (BDBiosciences). Absolute quantification of leukocytes was assessed using the TRUCOUNT method (BDBiosciences).

**Quantification of circulating chemokines and cytokines.** Plasma was isolated from fresh blood samples collected in EDTA tubes, following centrifugation for 20 min at 3000 rpm at 4°C; the plasma samples were then immediately stored at -80°C. Circulating concentrations of cytokines and chemokines were quantified from 25-µl non-diluted aliquots of the plasma samples using a Milliplex 29-plex human cytokine/chemokine magnetic bead panel (Millipore) and a Luminex® analyzer (MAGPIX), according to the manufacturer’s instructions.

**Measurement of circulating immunoglobulins.** Circulating concentrations of cytokines and chemokines were quantified from plasma samples (50-µl 1/16,000 diluted samples) using a Milliplex human immunoglobulin (IgA, IgM, IgG1, IgG2, IgG3, and IgG4) isotyping magnetic bead panel (Millipore) and a Luminex® analyzer (MAGPIX), according to the manufacturer’s instructions. Plasma samples from healthy individuals were included as controls.

**Statistical analyses.** Values are given as medians and interquartile ranges (Q1–Q3). Comparisons of two groups were performed using the Mann–Whitney test. Comparisons of more than two groups were performed using the Kruskal–Wallis test with a Dunn’s comparison test. The impacts of the *BRAF*V600E mutation and treatment with first-line therapies on blood leukocyte counts were tested using the Jonckheere-Terpstra trend test. Correlations were calculated using the Spearman rank-order test. A χ2 test was performed to analyze the distribution of ECD individuals according to the *BRAF* status around the median value of the indicated parameter. For skewed variables, the raw data were logarithmically transformed prior to conducting the analyses. Statistical analyses were performed using R statistical software version 3.3.2 (R foundation for Statistical Computing) and Prism software from GraphPad (San Diego, CA USA). Principal component analysis was performed using the public MetaboAnalyst web server (<https://www.metaboanalyst.ca/>).

**Results**

**Profound alteration of the systemic immune cell phenotype in ECD**. Flow cytometry analysis of blood immune cells in patients with ECD allowed the identification of the complete set of monocytes (classical, intermediate, and nonclassical), DCs (plasmacytoid (pDC), myeloid 1 (mDC1), and 2 (mDC2)), and lymphocytes (T helper (Th), cytotoxic (CT), T regulatory (Treg), natural killer (NK), and B) in a similar fashion than in control individuals independently of the *BRAF*V600E mutation (**Supplementary Figure 1**). As shown in **Supplementary Figure 1**, no atypical population was detected in ECD patients irrespective of their *BRAF* status in comparison with control individuals. Although the number of total blood monocytes was higher in patients with ECD who had the *BRAF*-mutation in comparison with total blood monocytes in the controls (+58.9%, p<0.05), none of the monocyte subsets was found to be significantly increased in those individuals (**Table 1**). Instead, a trend for a decrease in nonclassical CD14+CD16++ monocytes was observed in ECD patients carrying the *BRAF*V600E mutation (-73.8%, p<0.08). More strikingly, a marked decrease in the absolute count of DCs, including pDCs (-63.6%, p<0.0005), mDC1s (-62.0%, p<0.05), and mDC2s (-72.6%, p<0.005), was observed in patients with ECD when compared with these values in healthy individuals; this effect mostly reflected the reduction in all DC subsets in patients with the *BRAF*-mutation. Such effects were independent of a patient’s sex (data not shown). Although the number of blood neutrophils, NK, NKT, and Treg cells was not altered in patients with ECD, we noticed a large decrease in CT (-80.8%, p<0.0005) and B (-66.5%, p<0.005) lymphocytes in ECD patients relative to the counts for these cells in controls. Finally, a substantial reduction in the absolute count of Th lymphocytes (-84.5%, p<0.05) was observed in nonmutated ECD patients.

Principal component analysis of the blood immune cell populations of individuals in the control and ECD groups illustrated the unusual systemic immune signature that characterized ECD **(Figure 1A),** as well as a potential effect of the *BRAF*V600E mutation, as was suggested by the analysis of individual cell populations **(Table 1)**. Assessment of the impactof the *BRAF*V600E mutation on populations of blood immune cells in ECD supports an enhancing effect of the mutation on the reduction in blood nonclassical CD14+CD16++ monocyte (p<0.03) and DC (pDC, p<0.0002; mDC1, p<0.05, and mDC2, p<0.0009) numbers and on the increase in blood total monocytes (p<0.04) in ECD patients compared with control individuals **(Figure 1B-I)**.

Analysis of the effect of first-line therapies on this disturbed systemic immune cell signature indicated that patients with ECD who also had the *BRAF* mutation and who were treated with first-line therapies, including pegylated IFNα (pegIFNα) and vemurafenib, did not exhibit such a massive alteration of the systemic immune cell phenotype when compared with control individuals **(Table 1)**. As an illustration, the absolute counts of mDC1 and mDC2 populations in treated ECD patients carrying the *BRAF*V600E mutation were not significantly different from those of control individuals. Assessment of the impact of first-line therapies in ECD patients with the *BRAF* mutation highlighted the capacity of treatments to partially correct or restore the circulating numbers of several altered leukocyte populations in ECD; this was observed for nonclassical CD14+CD16++ monocyte (p<0.03), mDC1 (p<0.03), and mDC2 (p<0.0006) populations **(Figure 2)**. However, treatments taken individually or as a whole were unable to restore the decrease in pDC populations in patients with ECD **(Table 1 and Figure 2)**.

Taken together, these findings highlighted a major perturbation of the systemic immune cell phenotype in ECD cases, characterized by a deficit of DCs and lymphocytes, which could be partially restored by first-line treatments in patients with the *BRAF*-mutation.

**Impact of first-line therapies on the systemic cytokine and chemokine network in ECD.**

To provide clues about the mechanism underlying the alteration of the systemic immune cell phenotype according to the *BRAF* status of patients with ECD, a comprehensive quantification of circulating chemokines and cytokines was performed on this single-center group of 78 patients with ECD **(Supplemental Table 2)**. As previously reported 6, the levels of many circulating cytokines and chemokines are highly heterogeneous among ECD patients **(Supplemental Table 2)**. However, when we investigated the impact of the *BRAF*V600E mutation on ECD patients’ cytokine and chemokine profiles, we observed that the proportion of individuals with high levels of numerous circulating cytokines driving the Th1 response (IL-6, IL-8, IL-12p40, and TNFα) and chemokines (IP-10, CCL2, MIP-1α, and CCL22) was higher in carriers of the *BRAF*V600E mutation in comparison with noncarriers **(Figure 3)**. It is noteworthy that patients with the *BRAF*-mutation also exhibited high levels of anti-inflammatory IL-10. In contrast, a higher proportion of patients with elevated circulating levels of eotaxin, EGF, and IL-15 was detected among patients lacking the *BRAF* mutation than in their counterparts with the *BRAF* mutation. Because of the specific mode of action of the treatments, i.e., vemurafenib and pegIFNα, no difference in the circulating concentrations of cytokines and chemokines was detected between ECD patients with the *BRAF* mutation who were treated or not treated with first-line therapies when taken as a whole **(Supplemental Table 2)**. Conversely, compared with their nontreated counterparts,ECD patients with the *BRAF* mutation who were treated with pegIFNα exhibited higher circulating levels of cytokines that drove either a pro-inflammatory Th1 (IFNα, 5.6-fold, p<0.0001; and IL-15, 1.8-fold, p<0.05) or anti-inflammatory Th2 (IL-10, 1.9-fold, p<0.05) response, as well as chemokines (IP-10, 1.5-fold, p<0.05; and CCL2, 1.3-fold, p<0.05) and a cytokine involved in hematopoiesis (GCSF; 2.2-fold, p<0.05) **(Supplemental Table 2)**. However, it is worth mentioning that there was a reduction in plasma CCL22 levels (-34%, p<0.05) in ECD patients carrying the *BRAF*V600E mutation, after they received pegIFNα treatment. A similar pegIFNα signature was observed when all patients with ECD were considered, irrespective of their *BRAF* status (data not shown). Finally, a significant reduction in plasma CCL2 levels was only observed in ECD patients upon vemurafenib therapy compared with untreated ECD patients carrying the *BRAF* mutation (-49.5%, p<0.05) **(Supplemental Table 2)**.

Taken together, our results show that patients with ECD and who carried the *BRAF*V600E mutation exhibited an overall more pro-inflammatory cytokine and chemokine signature than ECD patients who did not carry this mutation, which appears further exacerbated by pegIFNα treatment.

**Interrelationship between blood immune cell phenotype and cytokine and chemokine network in ECD.**

We next investigated whether the modifications to the circulating cytokine and chemokine concentrations may translate to the major perturbation of the systemic immune cell phenotype, as well as its partial restoration following first-line therapy, in ECD patients carrying the *BRAF* mutation. For this purpose, circulating immune cell numbers were correlated to concentrations of cytokines and chemokines in the whole ECD cohort. As shown in **Supplemental Table 3**, although none of these biomolecules were found to be correlated with blood B or Th lymphocytes, the results indicated that the absolute count of nonclassical monocytes (CD14+CD16++) was positively correlated with the plasma concentrations of IFNα2 (r=0.31, p<0.005), IL-6 (r=0.30, p<0.05), IL-8 (r=0.23, p<0.05), and IL-5 (r=0.27, p<0.05). Interestingly, plasma IP-10 levels were positively correlated with the abundance in the blood of both nonclassical monocytes (r=0.31, p<0.05) and mDC2 cells (r=0.28, p<0.05), while a correlation was detected between TNFα and MIP-1β levels with the mDC1 number (r=0.40, p<0.0005) and CT lymphocytes (r=-0.24, p<0.05).

As a whole, these findings have led to the identification of a set of cytokines and chemokines that might account for the abundance of nonclassical monocytes and myeloid DCs following first-line therapies in the blood of ECD patients who carry the *BRAF* mutation.

**Immunoglobulin switch toward immunoglobulin G4 in ECD.**

 Finally, to determine if the disturbance of the systemic immune cell phenotype translates into a defect in immunoglobulin production, plasma concentrations of immunoglobulin isotypes (IgA, IgM, IgG1, IgG2, IgG3, and IgG4) were quantified in patients with untreated ECD. Although the quantities of IgA and IgM were within the reference ranges for adults 12, those of IgG were more elevated, which mostly reflected the high abundance of IgG4 and, to a lesser extent, high concentrations of IgG2 13 **(Supplemental Table 4)**. As a result, in patients with ECD, the proportion of IgG1 (IgG1/IgGs) was low, whereas that of IgG4 (IgG4/IgGs) was high; this effect appeared to be more pronounced in patients carrying the *BRAF* mutation. Analysis of the patient distribution according to their IgG4 levels (normal < 135 and high ≥ 135 mg/dL) 14 indicated that whereas a roughly similar proportion of patients without the *BRAF* mutation displayed either normal or high levels of IgG4, that of patients carrying the *BRAF*V600E mutation was 1.7-fold higher than that of patients who lacked the mutation in the normal IgG4 group and up to 3-fold higher in the high IgG4 group **(Figure 4A)**. On the whole, 64.7% of patients with ECD exhibited a high-IgG4 immune phenotype, with a predominance of *BRAF*-mutated patients. Strikingly, first-line therapies corrected the IgG switch in this latter group, with a significant increase in IgG1 being observed upon pegIFNα therapy (untreated, 30.9 (25.3–43.8) versus pegIFNα, 50.3 (36.1–58.3), p<0.005), while IgG4 returned to normal values following vemurafenib treatment (untreated, 16.5 (6.51–37.4) versus vemurafenib, 4.69 (2.02–7.94), p<0.05) **(Figure 4)**. A similar correction of the IgG profile was also observed for the entire ECD cohort treated with first-line therapies **(Supplemental Figure 2)**. These findings revealed that patients with ECD exhibited an IgG switch, from IgG1 to IgG4, which was corrected by first-line therapies.

**Discussion**

The present study, involving a single-center series of 78 patients with ECD, revealed a profound perturbation of the blood immune phenotype in these patients, characterized by a decrease in the DC and lymphocyte populations and accompanied by a switch in IgG subclasses. This perturbation was exacerbated in patients carrying the *BRAF*V600E mutation, who also exhibited a higher pro-inflammatory status than patients who lacked this mutation. First-line therapies were able to partially correct the altered immune cell phenotype and restore the IgG pattern.

 This first comprehensive analysis of systemic immune cell populations in patients with ECD revealed an unusual ECD signature, characterized by a very low abundance of DCs, including pDC, mDC1, and mDC2, in comparison with the abundance of these cells in matched control individuals. Although there is limited information available about the levels of immune cells in the blood of patients with histiocytosis, this observation contrasts with the increased quantity of DC precursors detected in the blood of patients with Langerhans cell histiocytosis (LCH), a histiocytic neoplasm that arises from the dendritic lineage 15. Although a trend for such a decrease in DCs was observed in patients who lacked the *BRAF* mutation, a much stronger effect was detected in patients who did carry this mutation, suggesting that the activation of the ERK signaling pathway could underlie this phenotype. This perturbation in blood DC levels was unlikely to have resulted from the increased infiltration of these cells into tissues, as no CD123-positive cells (pDCs) have previously been detected in ECD lesions 6. Rather, activation of the MEK/ERK signaling pathway was reported to inhibit the maturation of monocyte-derived DCs 16,17. More recently, Hogstad et al. elegantly demonstrated that the MAPK pathway, including the *BRAF*V600E mutation, suppresses DC migration and traps DCs in LCH lesions 18. *BRAF* mutations have been detected in myeloid progenitors in bone marrow from ECD patients 2; therefore, our findings lead us to propose that the presence of the *BRAF*V600E mutation in myeloid DC precursors might cause these cells to be retained in the bone marrow compartment and impede their migration to the blood circulation. This mechanism could explain the paradoxical elevated systemic IFNα concentrations reported in patients with ECD 6, despite the low abundance of blood DCs presently described. Additional investigations are needed to determine if an increase in myeloid DC precursors can be detected in the bone marrow of patients with ECD.

 Antigen-presenting cells such as DCs interact with lymphocytes and contribute to their proliferation and maturation and the establishment of an immune response. Together with the decrease in blood DCs, the systemic concentrations of helper, cytotoxic, and B lymphocytes were markedly reduced in patients with ECD in the present study. Moreover, decreased systemic levels of IL-7, a cytokine involved in B and T lymphocyte differentiation, have been reported in patients with ECD 6. The infiltration of Th1 cells into ECD lesions 4 could also contribute to the reduction in the abundance of circulating T lymphocytes. Indeed, CCL19/MIP-3β, a chemo-attractant for B and T lymphocytes and DCs, was reported to be expressed in ECD lesions that were analyzed by immunohistochemistry 4. In contrast, the expansion of Treg lymphocytes alone in both the blood compartment and lesions has been reported in LCH, while monocyte and DC populations were not altered 19.

 Despite the low abundance of circulating B cells, a recent study pointed out the high prevalence (42%) of autoimmunity in patients with ECD 20. Here, we brought to light perturbations in the IgG profile characterized by high IgG4 levels and leading to an IgG1/IgG4 switch. A few case reports have documented high IgG4 levels in ECD patients, proposing ECD as a mimic of IgG4-related disease (IgG4-RD) 14,21. In a review of a single-center cohort, Gianfreda et al. observed that high levels of IgG4 were present in 26.7% (4/15) of patients with ECD 14. In the present study, involving 78 patients, high levels of IgG4 (<135 mg/dL) were observed more frequently, affecting 64.7% of patients. However, while ECD and IgG4-RD share some physiopathological characteristics, these diseases exhibit distinctive clinical features, suggesting they are distinct disorders. The increased production of IgG4 is frequently driven through a Th2 response to IL-4, IL-5, or Il-13 and by anti-inflammatory IL-10 and TGFβ cytokines 22. Although ECD patients exhibit a Th1 immune response 4,6, the present study suggested that while patients who carry the *BRAF* mutation are more likely to exhibit high IgG4 levels than patients who lack the mutation, both exhibit higher circulating IL-10 concentrations, suggesting that IL-10 might contribute to the IgG4 immune response in ECD. Moreover, IFNα, which is secreted by pDCs and initiates the Th1 response and whose systemic concentrations are elevated in ECD 6, has been reported to increase IgG4 production by B lymphocytes 23. Thus, infiltration of pDCs in pancreatic lesions of patients with IgG4-related autoimmune pancreatitis has been proposed to induce IgG4 production by plasma cells via IFNα 23. Similar to what is observed in cases of IgG4-RD, IgG4-positive plasma cell infiltrates were observed in ECD lesions at perirenal and subcutaneous sites 14. To determine whether the reduction in circulating B cells in ECD detected in the present study reflects the infiltration of these cells into lesions or impaired B cell differentiation deserves further investigation.

 The quantification of serum cytokines in a single-center series of 37 patients with ECD was previously reported; it included the identification of an ECD signature based on the concentrations of IFNα2, IL-12, MCP-1, IL-4, and IL-7 that allowed ECD patients to be distinguished from control individuals 6. The present study provides new information regarding the effect of the *BRAF*V600E mutation on this ECD signature, as well as on the systemic immune Th1 phenotype that characterizes ECD. We found an exacerbated Th1-mediated systemic immune response in patients carrying the *BRAF* mutation, characterized by a higher proportion of participants carrying the *BRAF*V600E mutation with elevated circulating concentrations of pro-inflammatory cytokines (IL-12p40, IL-6, IL-8, and TNFα) and chemokines (IP-10, CCL2, CCL22, and MIP-1α) than participants who lacked this mutation. However, first-line therapies were unable to dampen this pro-inflammatory phenotype. Elevated levels of circulating chemokines in patients carrying the *BRAF* mutation are consistent with previous studies reporting that the presence of the *BRAF*V600E mutation is a major determinant in histiocyte infiltration 24 and that vemurafenib shows a high efficacy in multisystemic and refractory ECD 8. The decrease in CCL2 concentrations in ECD patients treated with vemurafenib in comparison with their untreated counterparts carrying the *BRAF* mutation might account, at least in part, for the reduced infiltration upon receiving this therapy. An analysis of the systemic chemokine and cytokine network in 52 patients with LCH versus 34 control individuals revealed that patients carrying the *BRAF*V600E mutation only showed elevated levels of MCP-3 in serum, with no other abnormalities detected 25. Such an elevation of MCP-3 was not observed in patients carrying the *BRAF* mutation in the present study.

First-line therapies, although having a modest impact on the systemic chemokine and cytokine concentrations, were able to correct most of the alterations in blood immune cell counts, especially those of nonclassical CD14+CD16++ monocytes, mDC1s, mDC2s, and B lymphocytes, whereas they failed to restore those of pDCs. While disturbances in the immune response were more frequent in ECD patients carrying the *BRAF* mutation, targeted therapy appeared to be less effective than pegIFNα to improve these patients. Nevertheless, vemurafenib, similarly to pegIFNα, corrected the IgG1/IgG4 switch. The major findings of the present study are summarized in **Figure 5**.

 In conclusion, our study is the first report of the marked alteration of the systemic immune response in ECD and brings to light the involvement of DCs in this non-LCH neoplasm. This new information will help in our understanding of the mechanisms taking place in ECD and provides additional clues to the best approach to the therapeutic management of patients with ECD.

**Limitations of the study.** The limitations of this study include the relatively low number of patients with ECD on the different therapies (vemurafenib versus pegIFNα). Another limitation is the absence of data from ECD patients before and after treatment, which would be useful to investigate in more detail the impact of first-line therapies on the systemic disturbance of the immune cell phenotype and the IgG switch. Finally, the inclusion of a control group comprising patients with LCH would have helped to precise the specific inflammatory patterns in ECD.

**Acknowledgments**

The authors are indebted to all the participants for their cooperation. This work was financially supported by INSERM, Sorbonne Université, French National Agency (ANR-10-IAHU-05) and the Erdheim-Chester Disease Global Alliance.

**Author contribution.**

FCA, LP, FS-C, YA, EF, and WLG performed the research. FCA, PL, JH, and WLG designed the research. FCA and JH recruited the patients. MG and WLG analyzed the data. JH and WLG funded the research. All authors gave critical comments on the manuscript. WLG supervised the study and wrote the manuscript.

**Conflict-of-interest disclosure.**

The authors declare no competing financial interests.

**References**

1. Durham BH. Molecular characterization of the histiocytoses: Neoplasia of dendritic cells and macrophages. Seminars in Cell & Developmental Biology 2019;8662–76.

2. Milne P, Bigley V, Bacon CM, et al. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood 2017;130(2):167–175.

3. Durham BH, Roos-Weil D, Baillou C, et al. Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood 2017;130(2):176–180.

4. Stoppacciaro A, Ferrarini M, Salmaggi C, et al. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: Implications for pathogenesis. Arthritis Rheum 2006;54(12):4018–4022.

5. Dagna L, Girlanda S, Langheim S, et al. Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis. Rheumatology 2010;49(6):1203–1206.

6. Arnaud L, Gorochov G, Charlotte F, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood 2011;117(10):2783–2790.

7. Cohen-Aubart F, Maksud P, Emile J-F, et al. Efficacy of infliximab in the treatment of Erdheim-Chester disease. Ann Rheum Dis 2018;77(9):1387–1390.

8. Haroche J, Cohen-Aubart F, Emile J-F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013;121(9):1495–1500.

9. Goyal G, Heaney ML, Collin M, et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood 2020;135(22):1929–1945.

10. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012;120(13):2700–2703.

11. Szalat R, Pirault J, Fermand J-P, et al. Physiopathology of necrobiotic xanthogranuloma with monoclonal gammopathy. J Intern Med 2014;276(3):269–284.

12. Gonzalez-Quintela A, Alende R, Gude F, et al. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities: Serum immunoglobulin levels in adults. Clinical & Experimental Immunology 2008;151(1):42–50.

13. Schauer U, Stemberg F, Rieger CHL, et al. IgG Subclass Concentrations in Certified Reference Material 470 and Reference Values for Children and Adults Determined with The Binding Site Reagents. Clinical Chemistry 2003;49(11):1924–1929.

14. Gianfreda D, Musetti C, Nicastro M, et al. Erdheim-Chester Disease as a Mimic of IgG4-Related Disease: A Case Report and a Review of a Single-Center Cohort. Medicine 2016;95(21):e3625.

15. Rolland A, Guyon L, Gill M, et al. Increased Blood Myeloid Dendritic Cells and Dendritic Cell-Poietins in Langerhans Cell Histiocytosis. J Immunol 2005;174(5):3067–3071.

16. Puig-Kröger A, Relloso M, Fernández-Capetillo O, et al. Extracellular signal-regulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells. Blood 2001;98(7):2175–2182.

17. Aguilera-Montilla N, Chamorro S, Nieto C, et al. Aryl hydrocarbon receptor contributes to the MEK/ERK-dependent maintenance of the immature state of human dendritic cells. Blood 2013;121(15):e108-117.

18. Hogstad B, Berres M-L, Chakraborty R, et al. RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med 2018;215(1):319–336.

19. Senechal B, Elain G, Jeziorski E, et al. Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS Med 2007;4(8):e253.

20. Roeser A, Cohen-Aubart F, Breillat P, et al. Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors. Haematologica 2019;104(11):e502–e505.

21. Miron G, Karni A, Faust-Soher A, Giladi N, Alroy H, Gadoth A. Erdheim-Chester disease presenting with chorea and mimicking IgG4-related disorder. Neurol Clin Pract 2019;9(6):524–526.

22. Liu C, Zhang P, Zhang W. Immunological mechanism of IgG4-related disease. J Transl Autoimmun 2020;3100047.

23. Arai Y, Yamashita K, Kuriyama K, et al. Plasmacytoid Dendritic Cell Activation and IFN-α Production Are Prominent Features of Murine Autoimmune Pancreatitis and Human IgG4-Related Autoimmune Pancreatitis. J Immunol 2015;195(7):3033–3044.

24. Cohen-Aubart F, Guerin M, Poupel L, et al. Hypoalphalipoproteinemia and *BRAF* V600E Mutation Are Major Predictors of Aortic Infiltration in the Erdheim-Chester Disease. ATVB 2018;38(8):1913–1925.

25. Morimoto A, Oh Y, Nakamura S, et al. Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis. Cytokine 2017;9773–79.

**Legends to Figures**

**Figure 1. Patients with ECD are characterized by an unusual systemic immune cell signature.** A. Principal component analysis and blood counts of total (B) and nonclassical (C) monocytes, T helper (D), cytotoxic (E) and B (F) lymphocytes, and plasmacytoid (G), and myeloid 1 (H) and 2 (I) dendritic cells in untreated ECD patients according to their *BRAF* status in comparison with individuals in the control group. Controls, n=17; ECD patients without the mutation (WT), n=11; and ECD patients carrying the *BRAF*V600E mutation (V600E), n=23. *P* for trend was assessed using the Jonckheere-Terpstra trend test.

**Figure 2. Impact of first-line therapies on the systemic immune cell signature in ECD patients carrying the *BRAF* mutation.** A. Principal component analysis and blood counts of total (B) and nonclassical (C) monocytes, T helper (D), cytotoxic (E) and B (F) lymphocytes, and plasmacytoid (G), and myeloid 1 (H) and 2 (I) dendritic cells in untreated or treated ECD patients carrying the *BRAF*V600E mutation in comparison with individuals in the control group. Controls (n=17), untreated (n=23), and treated (n=29) ECD patients carrying the *BRAF*V600E mutation (V600E). Treatments included pegylated interferon α and vemurafenib. *P* for trend was assessed using the Jonckheere-Terpstra trend test.

**Figure 3. Impact of the *BRAF*V600E mutation on the systemic chemokine and cytokine network in patients with ECD.** Analysis of the repartition of untreated ECD patients according to their *BRAF* status around the median value of systemic concentrations of IL-6 (A), IL-12p40 (B), IL-15 (C), TNFα (D), IL-10 (E), CCL2 (F), CCL22 (G), eotaxin (H), IL-8 (I), IP-10 (J), MIP-1α (K), and EGF (L). Nonmutated ECD patients (WT), n=9 and ECD patients carrying the *BRAF*V600E mutation (V600E), n=21. Statistical significance was tested using a χ2 test.

**Figure 4. Correction of the IgG1/IgG4 switch by first-line therapies in patients carrying the *BRAF* mutation.** Prevalence of the high-level of IgG4 phenotype in untreated ECD patients according to the presence of the *BRAF*V600E mutation. Normal IgG4 < 135 mg/dL, high IgG4 ≥ 135 mg/dL. Nonmutated ECD patients (WT), n=9 and ECD patients carrying the *BRAF*V600E mutation (V600E), n=22. Impact of first-line therapies on the percentage of IgG1 (B), IgG2 (C), IgG3 (D), and IgG4 (E). Untreated (n=22) and treated (n=27; pegIFNα=16 and vemurafenib=11) ECD patients carrying the *BRAF*V600E mutation (V600E). Differences between groups were tested using the Kruskal–Wallis test. \*p<0.05 and \*\*p<0.005 versus untreated ECD patients carrying the *BRAF*V600E mutation.

**Figure 5. Major alterations of the systemic immune cell phenotype in patients with ECD.** Flow cytometry analysis of blood leukocytes in patients with ECD revealed a marked decrease in dendritic cells (pDC, mDC1, and mDC2) and lymphocytes (CTL and BL), as well as a reduction in NC monocytes in comparison with levels of these cells in individuals in the control group. Such a reduction in antigen-presenting cells might impair the activation of CTLs and BLs and the production of IgG, leading to an IgG switch toward IgG4. These alterations were mostly observed in ECD patients carrying the *BRAF*V600E mutation (in red), who exhibited a more pronounced systemic inflammation. First-line therapies partially corrected the systemic immune cell phenotype and normalized blood IgG concentrations. BL: B lymphocytes; CTL: cytotoxic T lymphocytes; IgG: immunoglobulin G; NC: nonclassical; mDC: myeloid dendritic cells; pDC: plasmacytoid dendritic cells.